Medigus Ltd. (MDGS): Price and Financial Metrics


Medigus Ltd. (MDGS): $0.66

0.01 (+2.02%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MDGS POWR Grades


  • MDGS scores best on the Sentiment dimension, with a Sentiment rank ahead of 92.03% of US stocks.
  • MDGS's strongest trending metric is Growth; it's been moving up over the last 61 days.
  • MDGS ranks lowest in Quality; there it ranks in the 0th percentile.

MDGS Stock Summary

  • Of note is the ratio of Medigus Ltd's sales and general administrative expense to its total operating expenses; 97.76% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of 473.03%, Medigus Ltd's debt growth rate surpasses 97.05% of about US stocks.
  • As for revenue growth, note that MDGS's revenue has grown 944.32% over the past 12 months; that beats the revenue growth of 98.94% of US companies in our set.
  • Stocks that are quantitatively similar to MDGS, based on their financial statements, market capitalization, and price volatility, are NBRV, XERS, PWFL, REFR, and DTSS.
  • MDGS's SEC filings can be seen here. And to visit Medigus Ltd's official web site, go to www.medigus.com.

MDGS Valuation Summary

  • MDGS's EV/EBIT ratio is -0.3; this is 101.02% lower than that of the median Healthcare stock.
  • Over the past 74 months, MDGS's price/sales ratio has gone up 3.4.
  • MDGS's EV/EBIT ratio has moved up 2.8 over the prior 74 months.

Below are key valuation metrics over time for MDGS.

Stock Date P/S P/B P/E EV/EBIT
MDGS 2021-08-31 45.6 1.1 -3.5 -0.3
MDGS 2021-08-30 42.6 1.0 -3.3 0.0
MDGS 2021-08-27 43.5 1.0 -3.4 -0.1
MDGS 2021-08-26 44.1 1.0 -3.4 -0.2
MDGS 2021-08-25 45.6 1.1 -3.5 -0.3
MDGS 2021-08-24 45.0 1.0 -3.5 -0.2

MDGS Growth Metrics

  • Its 4 year net cashflow from operations growth rate is now at 33.63%.
  • The 5 year revenue growth rate now stands at -14.81%.
  • The 5 year price growth rate now stands at -97.65%.
MDGS's revenue has moved down $92,328 over the prior 61 months.

The table below shows MDGS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2020-12-31 0.531 -6.143 -6.85
2019-12-31 0.273 -2.757 -14.178
2018-12-31 0.436 -4.253 -6.598
2017-12-31 0.467 -4.659 -2.545
2016-12-31 0.549 -9.255 -9.007
2015-12-31 0.623328 -6.945102 -9.54729

MDGS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MDGS has a Quality Grade of F, ranking ahead of 2.24% of graded US stocks.
  • MDGS's asset turnover comes in at 0.023 -- ranking 164th of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows MDGS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.023 -0.947 -1.494
2019-12-31 0.022 -0.667 -12.213
2018-12-31 0.047 -0.392 -4.972
2017-12-31 0.078 -0.105 -1.353
2016-12-31 0.065 0.679 -60.057
2015-12-31 0.047 0.556 -8.106

MDGS Stock Price Chart Interactive Chart >

Price chart for MDGS

MDGS Price/Volume Stats

Current price $0.66 52-week high $2.45
Prev. close $0.65 52-week low $0.62
Day low $0.63 Volume 151,500
Day high $0.69 Avg. volume 141,406
50-day MA $0.84 Dividend yield N/A
200-day MA $1.12 Market Cap N/A

Medigus Ltd. (MDGS) Company Bio


Medigus Ltd. develops endoscopic procedures and devices for the treatment of gastroesophageal reflux disease.


MDGS Latest News Stream


Event/Time News Detail
Loading, please wait...

MDGS Latest Social Stream


Loading social stream, please wait...

View Full MDGS Social Stream

Latest MDGS News From Around the Web

Below are the latest news stories about Medigus Ltd that investors may wish to consider to help them evaluate MDGS as an investment opportunity.

Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on February 24, 2022

Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its quarterly Emerging Growth Invitational investor conference on February 24, 2022. The conference, which is open to all retail and institutional investors, will consist of a series of twenty five

Yahoo | February 15, 2022

Medigus: Charging Robotics and Ben-Gurion University to Develop the Next Generation of Wireless Charging System for Electric Vehicles

Tel Aviv, Israel, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, announced today that its wholly-owned subsidiary, Charging Robotics Ltd. and BGN Technologies, the technology transferred company of Ben-Gurion University signed an agreement to develop the next generation of Charging Robotics' wireless charging system for electric vehicles. Once

Yahoo | February 15, 2022

Medigus Announces First Authorization For Commercial Drone Deliveries in Brazil

Tel Aviv, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, announced today that ParaZero Ltd. ("ParaZero"), a privately held company engaged in drone technology with an innovative patented safety system for drones, of which Medigus has a 40% ownership stake, confirmed that a drone carrying its ParaZero SafeAirTM system was granted the fir

Yahoo | February 14, 2022

Clearmind Medicine Secures CAD$1.6 Million in Private Placement

Clearmind and Medigus, the investor, intend to form a joint venture in the field of food industry, based on Clearmind's unique psychedelics IPTORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announced today it has signed an agreement f

Yahoo | February 8, 2022

Medigus Enters Psychedelics Market with Investment in Clearmind, a Psychedelic Pharmaceutical Biotech Company

The parties intend to form a joint venture in the food industry, based on Clearmind's unique psychedelics IPTel Aviv, Israel, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, announced today the expansion of its healthcare activities by signing an investment agreement with Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF), a psychede

Yahoo | February 8, 2022

Read More 'MDGS' Stories Here

MDGS Price Returns

1-mo -18.63%
3-mo -38.60%
6-mo -40.54%
1-year -63.93%
3-year -72.61%
5-year -92.50%
YTD -34.00%
2021 -47.64%
2020 9.77%
2019 -33.08%
2018 -50.76%
2017 -76.84%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6184 seconds.